Benzinga · Aug 17, 2026
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment
Mesoblast finished patient dosing in its Phase 3 trial for a cellular back pain treatment, targeting a market worth over $10 billion.
ME
NASDAQ · MESO
Mesoblast Limited
Healthcare · Biotechnology
$17.43
Down-$0.48 (-2.75%)
Updated Aug 21, 2026, 1:51 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.36B
- P/E ratio
- -27.76
- Dividend yield
- 0.00%
- 52-week range
- $12.66 – $21.50
- Volume
- 273.59K
- Avg. volume
- 231.33K
Price performance
MESO price history
1M range · 21 trading sessions · Daily adjusted prices
MESO closed at $17.43 after 21 trading sessions, up 8.40% for the selected period.
- Last close
- $17.43
- Period change
- +8.40%
- Period low
- $14.13
- Period high
- $17.43
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $17.70 | $17.97 | $17.41 | $17.43 | 273.59K |
| Aug 19, 2026 | $16.85 | $17.14 | $16.78 | $17.13 | 132.46K |
| Aug 18, 2026 | $16.91 | $17.06 | $16.60 | $16.67 | 182.26K |
| Aug 17, 2026 | $17.21 | $17.48 | $16.84 | $17.02 | 458.4K |
| Aug 14, 2026 | $15.68 | $15.68 | $15.40 | $15.595 | 164.76K |
| Aug 13, 2026 | $16.78 | $16.78 | $16.30 | $16.49 | 139.84K |
| Aug 12, 2026 | $17.03 | $17.08 | $16.72 | $16.78 | 211.81K |
| Aug 11, 2026 | $16.89 | $17.04 | $16.82 | $16.92 | 143.67K |
| Aug 10, 2026 | $16.63 | $16.775 | $16.4901 | $16.68 | 295.76K |
| Aug 7, 2026 | $15.78 | $15.97 | $15.7114 | $15.94 | 80.93K |
| Aug 6, 2026 | $15.53 | $15.87 | $15.53 | $15.62 | 206.29K |
| Aug 5, 2026 | $14.94 | $15.12 | $14.89 | $14.96 | 80.71K |
| Aug 4, 2026 | $14.68 | $14.84 | $14.605 | $14.80 | 119.34K |
| Aug 3, 2026 | $14.12 | $14.55 | $14.00 | $14.47 | 228.64K |
| Jul 31, 2026 | $14.50 | $14.53 | $14.045 | $14.17 | 159.42K |
| Jul 30, 2026 | $14.32 | $14.57 | $14.32 | $14.55 | 179.42K |
| Jul 29, 2026 | $14.34 | $14.45 | $14.09 | $14.13 | 251.28K |
| Jul 28, 2026 | $14.66 | $14.66 | $14.05 | $14.45 | 209.62K |
| Jul 27, 2026 | $14.98 | $15.08 | $14.50 | $14.56 | 325.4K |
| Jul 24, 2026 | $15.77 | $15.77 | $15.23 | $15.31 | 188.31K |
| Jul 23, 2026 | $15.95 | $16.12 | $15.87 | $16.08 | 103.69K |
Latest MESO news
The latest Smart Investors Daily articles mentioning MESO.
Stock researchCompany · Overview
MESO research
Overview
Company profile and research snapshot.
Company profile
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $11.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | PIPER SANDLER COMPANIES | Overweight | — |
| Jul 12, 2026 | CANTOR FITZGERALD | Overweight | — |
| Jul 9, 2026 | CANACCORD GENUITY | Buy | — |
| Jul 9, 2026 | JEFFERIES | Buy | — |
| Jun 30, 2026 | BELL POTTER SECURITIES | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 12, 2026
Mesoblast Limited 2026 Q4 - Results - Earnings Call Presentation
2026-08-12. The following slide deck was published by Mesoblast Limited in conjunction with their 2026 Q4 earnings call.
Yahoo · Jul 17, 2026
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?
Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Yahoo · Jul 14, 2026
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemest
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
